Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDFNASDAQ:ICCCNASDAQ:KODNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$3.51+4.8%$2.86$2.01▼$5.64$233.51M1.611.15 million shs848,522 shsICCCImmuCell$6.87+1.3%$5.49$3.34▼$7.01$62.08M0.2322,236 shs10,623 shsKODKodiak Sciences$3.94+9.4%$3.35$1.92▼$11.60$207.89M2.42346,942 shs550,305 shsTNXPTonix Pharmaceuticals$40.45+6.3%$21.96$6.76▼$520.00$296.30M1.63898,124 shs924,098 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology+0.30%+10.56%+18.79%-10.19%+5.35%ICCCImmuCell+6.94%+3.99%+28.17%+30.38%+59.53%KODKodiak Sciences+4.35%+4.65%-25.00%-4.76%+13.21%TNXPTonix Pharmaceuticals-4.37%+31.56%+90.30%+387.95%-92.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDFCardiff Oncology1.5662 of 5 stars3.50.00.00.03.30.00.6ICCCImmuCell0.3601 of 5 stars0.03.00.00.02.80.00.0KODKodiak Sciences4.0759 of 5 stars3.03.00.04.61.53.30.6TNXPTonix Pharmaceuticals3.7767 of 5 stars3.54.00.00.03.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology 3.00Buy$12.00241.88% UpsideICCCImmuCell 0.00N/AN/AN/AKODKodiak Sciences 2.00Hold$9.00128.43% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,346.23% UpsideCurrent Analyst Ratings BreakdownLatest ICCC, KOD, TNXP, and CRDF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.003/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$587K397.80N/AN/A$1.56 per share2.25ICCCImmuCell$27.30M2.27N/AN/A$3.23 per share2.13KODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/ATNXPTonix Pharmaceuticals$10.04M29.51N/AN/A$5,751.80 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$41.44M-$0.92N/AN/AN/A-6,238.17%-73.97%-60.40%8/14/2025 (Estimated)ICCCImmuCell-$5.78M-$0.07N/A∞N/A-15.99%-15.32%-8.81%8/12/2025 (Estimated)KODKodiak Sciences-$260.49M-$3.63N/AN/AN/AN/A-84.52%-45.40%8/13/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$1,963.61N/AN/AN/A-1,197.86%-163.95%-118.88%8/15/2025 (Estimated)Latest ICCC, KOD, TNXP, and CRDF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ICCCImmuCellN/A$0.16N/A$0.16N/A$8.07 million5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million5/8/2025Q1 2025CRDFCardiff Oncology-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/A3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A4.744.74ICCCImmuCell0.363.111.44KODKodiak SciencesN/A8.428.42TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%ICCCImmuCell13.47%KODKodiak Sciences89.06%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology7.70%ICCCImmuCell6.60%KODKodiak Sciences45.30%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology2066.53 million47.15 millionOptionableICCCImmuCell709.04 million8.32 millionNot OptionableKODKodiak Sciences9052.76 million28.79 millionOptionableTNXPTonix Pharmaceuticals507.33 million1.87 millionNot OptionableICCC, KOD, TNXP, and CRDF HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 10.4% - Time to Buy?June 3 at 3:12 PM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 4.1% - What's Next?June 2 at 2:22 PM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to "Sell"June 1 at 2:07 AM | americanbankingnews.comZacks Small Cap Issues Optimistic Forecast for TNXP EarningsJune 1 at 1:21 AM | americanbankingnews.comTonix Pharmaceuticals (NASDAQ:TNXP) Cut to Sell at Wall Street ZenMay 31 at 12:31 AM | marketbeat.comTonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky BetMay 30, 2025 | seekingalpha.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.6% - Here's WhyMay 30, 2025 | marketbeat.comZacks Small Cap Brokers Boost Earnings Estimates for TNXPMay 30, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 9.1% - Should You Buy?May 29, 2025 | marketbeat.comJane Street Group LLC Purchases 1,635,119 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 29, 2025 | marketbeat.comWhat's Going On With Tonix Pharmaceuticals Stock?May 28, 2025 | benzinga.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 6% - Time to Sell?May 28, 2025 | marketbeat.comTNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia…May 28, 2025 | finance.yahoo.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 9% - Here's WhyMay 27, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.8% Higher - Still a Buy?May 25, 2025 | marketbeat.comPoint72 Asset Management L.P. Makes New $526,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 25, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street ZenMay 24, 2025 | marketbeat.comTonix Pharmaceuticals CEO Seth Lederman Participates in A.G.P. Annual Healthcare Company ShowcaseMay 22, 2025 | quiverquant.comTonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company ShowcaseMay 22, 2025 | globenewswire.comTonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress ReactionMay 21, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Pass Above 200-Day Moving Average - Here's WhyMay 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICCC, KOD, TNXP, and CRDF Company DescriptionsCardiff Oncology NASDAQ:CRDF$3.51 +0.16 (+4.78%) Closing price 04:00 PM EasternExtended Trading$3.70 +0.19 (+5.27%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.ImmuCell NASDAQ:ICCC$6.87 +0.09 (+1.33%) Closing price 04:00 PM EasternExtended Trading$6.65 -0.22 (-3.20%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Kodiak Sciences NASDAQ:KOD$3.94 +0.34 (+9.44%) Closing price 04:00 PM EasternExtended Trading$3.98 +0.04 (+1.14%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Tonix Pharmaceuticals NASDAQ:TNXP$40.45 +2.39 (+6.28%) Closing price 04:00 PM EasternExtended Trading$41.26 +0.81 (+2.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
